Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;66(2):241-243.
doi: 10.1007/s00108-024-01822-z. Epub 2024 Dec 30.

[Iscalimab-New treatment option for patients with primary Sjögren's disease]

[Article in German]
Arman Aue  1 , Thomas Dörner  2 , Sirka Nitschmann  3
Affiliations

[Iscalimab-New treatment option for patients with primary Sjögren's disease]

[Article in German]
Arman Aue et al. Inn Med (Heidelb). 2025 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Einhaltung ethischer Richtlinien. Interessenkonflikt: T. Dörner: Finanzierung von klinischen Studien (an die Charité) durch Novartis, die jedoch nicht Iscalimab betrifft. A. Aue und S. Nitschmann geben an, dass kein Interessenkonflikt besteht. Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

References

Literatur

    1. Ritter J, Chen Y, Stefanski AL, Dorner T (2022) Current and future treatment in primary Sjogren’s syndrome—A still challenging development. Joint Bone Spine 89:105406. https://doi.org/10.1016/j.jbspin.2022.105406 - DOI - PubMed
    1. Fisher BA et al (2024) Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren’s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet 404:540–553. https://doi.org/10.1016/S0140-6736(24)01211-X - DOI - PubMed
    1. Seror R et al (2015) Validation of EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74:859–866. https://doi.org/10.1136/annrheumdis-2013-204615 - DOI - PubMed
    1. St Clair EW et al (2024) CD40 ligand antagonist dazodalibep in Sjogren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med 30:1583–1592. https://doi.org/10.1038/s41591-024-03009-3 - DOI